Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 2Terminated 1

Sponsor Class

INDUSTRY 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 3Squamous Cell Carcinoma of Head and Neck 1Myelodysplastic Syndromes 1Lymphoma, B-Cell 1Hodgkin Disease 1Brain Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 358Cyclophosphamide 241Azacitidine 213fludarabine phosphate 199venetoclax 198fludarabine 196Busulfan 148Decitabine 132Mycophenolic Acid 123Whole-Body Irradiation 122Peripheral Blood Stem Cell Transplantation 118Tacrolimus 115Granulocyte Colony-Stimulating Factor 104Idarubicin 100Filgrastim 100Melphalan 89Cyclosporine 89Methotrexate 83Daunorubicin 76Antilymphocyte Serum 75Etoposide 73Mitoxantrone 67Clofarabine 67Gemtuzumab 59Stem Cell Transplantation 55Thiotepa 51Cladribine 46Injections 45Specimen Handling 44thymoglobulin 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Leukemia, Myeloid, Acute × magrolimab × Clear all
NCT04435691 2026-04-23

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

M.D. Anderson Cancer Center

Phase 1/2 Terminated
110 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

City of Hope Medical Center

Phase 1 Withdrawn
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05829434 2024-02-12

MAGROLIC

University of Leipzig

Phase 2 Withdrawn
Classical hematologyOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡